Myelodysplastic Syndromes (MDS)

Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Read more about Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry

Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes myelodysplastic syndromes:

Transplant and GVHD Session - 2025 Kansas City Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Bone Marrow Transplant

In this recording, Dr. Anurag Singh discusses transplant and potentials complications such as GVHD and treatment options. Recording includes the question-and-answer session.

Living Well with Bone Marrow Failure, from the 2025 Kansas City Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Living Well with Bone Marrow Failure

Managing Your Treatment

In this recording, Dr. Furha Cossor discusses living with bone marrow failure and fatigue management. Recording includes the question-and-answer session.

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study

Read more about Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study

Hypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes myelodysplastic syndromes:

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Read more about Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Read more about Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Read more about Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Context.—: Standardized bone marrow bone marrow: The soft, spongy tissue inside most bones.

Advancing drug development in myelodysplastic syndromes

Read more about Advancing drug development in myelodysplastic syndromes

Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone

Urge your Members of Congress to Reverse the 57% Cut to the Congressionally Directed Medical Research Program

Original Publication Date

April 14, 2025

Article Source

Take Action

Federal budget negotiations are already under way. April 15 marks the 30-Day anniversary of the enactment of the 57% cut to CDMRP including the elimination of all funding to Bone Marrow Failure Research. Every medical research program at CDMRP directly impacts the health and…

2025 San Francisco - Bay Area Patient and Family Conference

Read more about 2025 San Francisco - Bay Area Patient and Family Conference

Recorded Sessions:

Nutrition for Aplastic Anemia, MDS, or PNH

Managing PNH Treatments

Advances in Aplastic Anemia

Subscribe to Myelodysplastic Syndromes (MDS)

NFL Player Teams Up with AAMDSIF